SavedAdd your journal

Journals / Van Tıp Dergisi / 2017 / Cilt: 24 - Sayı: 3

Examining Nesfatin-1 and Ghrelin Hormone in Severity of Depression

Şiddetli Depresyonda Nesfatin-1 ve Ghrelin Hormonunun İncelenmesi

SERMİN ALGÜL
ÖZLEM ERGÜL ERKEÇ
MEHMET KARA
Bilge KARA
OĞUZ ÖZÇELİK
Pages
141–145
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Further studies are needed to understand this relationship between MDD and nesfatin-1 and ghrelin levels.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The major depressive disorder (MDD) is a serious mental and psychiatric disease.
📊
Key Findings & Data:Previous studies have shown that MDD may have important effects on nesfatin-1 and acylated, desacylated ghrelin hormones.
💡
Conclusion & Impact:Further studies are needed to understand this relationship between MDD and nesfatin-1 and ghrelin levels.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The major depressive disorder (MDD) is a serious mental and psychiatric disease. Previous studies have shown that MDD may have important effects on nesfatin-1 and acylated, desacylated ghrelin hormones. In the present study, we aimed to examine changes the nesfatin-1 (anorexigenic) and ghrelin (orexigenic) levels in patients with severe MDD. Materials and Methods: Twenty subjects (10 patients with severe MDD and 10 healthy controls) participated in this study. Fasting venous blood samples were taken at onset of the study both patients and control groups. Serum acylated and desacylated ghrelin, nesfatin-1 levels were measured using ELISA methods. Results: The basal nesfatin-1 level in MDD was found to be significantly higher (3.97±0.1 ng/mL) compared to the control group level (1.11±0.1 ng/mL) (p< 0.0001). Basal acylated (88.1±1.1 pg/ml) and desacylated ghrelin level (956.0±22.1 pg/ml) were found to be significantly lower in MDD group compared to the control (108.8±2.2 vs 1063.7±44.4 pg/mL), respectively (p< 0.0001). Conclusion: Observation of high nesfatin-1 and low acylated and desacylated ghrelin levels in patients with severe MDD compared to the control level could be an important criteria to evaluate patients current status. Further studies are needed to understand this relationship between MDD and nesfatin-1 and ghrelin levels.

Özet

Amaç: Major depresif bozukluk (MDB) şiddetli mental ve psikiyatrik bir hastalıktır. Daha önce yapılan çalışmalarda MDB'nin nesfatin-1 ve açile, desaçile ghrelin gibi hormonlarda önemli etkilere sahip olduğu gösterilmiştir. Bu çalışmada şiddetli MDB hastalarında nesfatin-1 (anoreksijenik) ve ghrelin (oreksijenik) düzeylerindeki değişikliklerin incelenmesi amaçlanmıştır. Gereç ve Yöntem: Bu çalışmaya 20 kişi (10 MDB ve 10 sağlıklı kontrol) katılmıştır. Açlık kan örnekleri çalışmanın başında hem hastalardan hem de kontrol grubundan alınmıştır. Serum açile ve desaçile ghrelin, nesfatin-1 düzeyleri ELISA metodu kullanılarak ölçülmüştür. Bulgular: MDB'de bazal nesfatin-1 düzeyi (3.97±0.1 ng/mL) kontrol grubunun düzeyiyle karşılaştırıldığında (1.11±0.1 ng/mL) anlamlı oranda yüksek bulunmuştur (p < 0.0001). MDB grubunun sırasıyla bazal açile (88.1±1.1 pg/ml) ve desaçile ghrelin düzeyleri (956.0±22.1 pg/ml) kontrolle karşılaştırıldığında (108.8±2.2 ve 1063.7±44.4 pg/mL), anlamlı olarak daha düşük bulunmuştur (p < 0.0001). Sonuç: Kontrol düzeyi ile karşılaştırıldığında anlamlı oranda yüksek nesfatin-1 ile anlamlı oranda düşük açile ve desaçile ghrelin düzeyleri hastaların mevcut durumunu değerlendirmek için önemli bir kriter olabilir. MDB ve nesfatin-1 ile ghrelin düzeyleri arasındaki ilişkiyi anlamak için daha ileri çalışmalara ihtiyaç duyulmaktadır.

🔖

Cite This Article

ALGÜL, S., ERKEÇ, Ö. E., KARA, M., KARA, B., ÖZÇELİK, O. (2017). Examining Nesfatin-1 and Ghrelin Hormone in Severity of Depression. Van Tıp Dergisi, Cilt: 24 - Sayı: 3, 141–145. https://ajindex.com/articles/334026

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Sun N, Yang CX, Liu ZF, Li XR, Xu Y, Zhang KR. Effects of polymorphisms of serotonin transporter promoter (5-HTTLPR) and brain derived neurotrophic factor gene (G196A rs6265) on the risk of major depressive disorder in the Chinese Han population. Eur Rev Med Pharmacol Sci 2016; 20(9): 1852-1859
  2. Song Z, Zhang M, Huang P. Aberrant emotion networks in early major depressive disorder patients: an eigenvector centrality mapping study. Transl Psychiatry 2016; 6: 819
  3. Li W, Sun H, Chen H, Yang X, Xiao L, Liu R, et al. Major Depressive Disorder and Kappa Opioid Receptor Antagonists. Transl Perioper Pain Med 2016; 1(2): 4-16
  4. Tripathi SM, Mishra N, Tripathi RK, Gurnani KC. P300 latency as an indicator of severity in major depressive disorder. Ind Psychiatry J 2015; 24(2): 163-167
  5. Lutter M, Sakata I, Osborne-Lawrence S, Rovinsky SA, Anderson JG, Jung S, et al. The orexigenic hormone ghrelin defends against depressive symptoms of chronic stress. Nat Neurosci 2008; 11(7): 752-753
  6. Hofmann T, Ahnis A, Elbelt U, Rose M, Klapp BF, Stengel A. NUCB2/nesfatin-1 is associated with elevated levels of anxiety in aneroxia nervosa. PLoS One 2015; 10(7): 0132058
  7. Oh-I S, Shimizu H, Satoh T, Okada S, Adachi S, Inoue K, et al. Identification of nesfatin- 1 as a satiety molecule in the hypothalamus. Nature 2006; 443(7112): 709-712
  8. Goebel M, StengelA, Wang L, Taché Y. Restraint stress activates nesfatin-1 immunoreactive brain nuclei in rats. Brain Res 2009; 1300: 114-124
  9. Bloem B, Xu L, Morava E, Faludi G, Palkovits M, Roubos EW, et al. Sex-specific differences in the dynamics of cocaine- and amphetamine-regulated transcript and nesfatin-1 expressions in the midbrain of depressed suicide victims vs. controls. Neuropharmacology 2012; 62(1): 297-303
  10. Bergmann K, Kretowicz M, Manitius J, Sypniewska G. Gender differences in association of serum nesfatin-1 with selected metabolic risk factors in normoglycemic subjects: A preliminary study. J Diabetes 2015; 7(3): 433- 434
  11. Tan BK, Hallschmid M, Kern W, Lehnert H, Randeva HS. Decreased cerebrospinal fluid/plasma ratio of the novel satiety molecule, nesfatin-1/NUCB-2, in obese humans: evidence of nesfatin-1/NUCB-2 resistance and implications for obesity treatment. J Clin Endocrinol Metab 2011; 96(4): 669-673
  12. Stengel A. Nesfatin-1 - More than a food intake regulatory peptide. Peptides 2015; 72: 175-183
  13. García-Galiano D, Tena-Sempere M. Emerging roles of NUCB2/nesfatin-1 in the metabolic control